Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05320835 · ClinicalTrials.gov registry record · NA
A Setting Focus Overdose Prevention Intervention
A NA study of HIV Infections and HCV, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Recruiting
- Registry status
- NA
- Development phase
- 285
- Enrollment target
- 1
- Study location
NCT05320835: Recruiting NA study of HIV Infections and HCV, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT05320835 is a NA study of HIV Infections and HCV that is actively recruiting participants, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 285 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05320835, a NA study of HIV Infections and HCV, is actively recruiting participants, sponsored by Johns Hopkins Bloomberg School of Public Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 285 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).
Primary Outcome
Frequency of carrying naloxone
Conditions Studied
Interventions
- BEHAVIORAL HIV, HCV and overdose prevention
Study Locations (1)
Maryland
- Lighthouse Studies at Peer Point - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2022-04-30 |
| Est. Completion | 2027-05-30 |
| Phase | NA |
What NCT05320835 shows while recruiting
NCT05320835 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (36% lower).
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which HIV, HCV and overdose prevention is the first listed.
NCT05320835 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05320835 about?
NCT05320835 is a clinical study titled "A Setting Focus Overdose Prevention Intervention". A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).
What is the current status of trial NCT05320835?
This trial is currently recruiting. It is a NA study. The enrollment target is 285 participants. The study started on 2022-04-30. Estimated completion is 2027-05-30.
What conditions does trial NCT05320835 study?
This clinical trial studies the following conditions: HIV Infections, HCV, Drug Overdose.
What interventions are being tested in trial NCT05320835?
The interventions under investigation include: HIV, HCV and overdose prevention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05320835?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05320835 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05320835's enrollment target sits among peer trials
285 129th of 542 higher than 414 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT06144164 · 285 participants · Phase 3
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI